Clinical Trials

72 enrolled

Advanced Non-small Cell Lung Cancer

NCT05498389 2023-06-01

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Phase 1/2 Unknown

115 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04974879 2023-03-29

Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer

20 enrolled

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05104281 2023-03-29

Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

Phase 3 Unknown

60 enrolled

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT02504346 2023-03-28

TREM

200 enrolled

Lung Neoplasms

NCT05785208 2023-03-27

TEMPLE-2

Phase 4 Unknown

122 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04811001 2023-02-21

CAPLAND

170 enrolled

NSCLC

NCT05583409 2022-10-17

SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC

Phase NA Unknown

72 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05458726 2022-07-26

Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05085054 2022-05-20

Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT)

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05284994 2022-03-17

TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer

Phase 1/2 Unknown

160 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05132777 2021-11-24

Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

155 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02824952 2021-11-18

Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02736513 2021-09-02

Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases

40 enrolled

CNSThoracic

Brain Neoplasms, Lung Neoplasms

NCT04816838 2021-08-25

A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR Mutations

Phase NA Unknown

25 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03257124 2021-08-16

Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS

80 enrolled

Non-Small Cell Lung Cancer With EGFR T790M Mutation

NCT04448379 2020-12-28

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

48 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03891615 2020-12-16

Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer

30 enrolled

Lung Neoplasms

NCT04029350 2019-08-21

ALTN-03

53 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02771314 2019-02-22

Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC

48 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02811354 2018-09-20

PLASMA

108 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03460275 2018-03-09

Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03424759 2018-02-07

Uncommon EGFR AZD9291

37 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03050411 2017-02-10

Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

30 enrolled